Auryxia Patent Expiration

AURYXIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9757416 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(4 months ago)

US8338642 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(4 months ago)

US9328133 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(4 months ago)

US7767851 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(4 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5753706 KERYX BIOPHARMS Methods for treating renal failure
Feb, 2022

(2 years ago)

US9050316 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(4 months ago)

US8754258 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(4 months ago)

US8754257 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(4 months ago)

US8846976 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(4 months ago)

US8901349 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(4 months ago)

US8609896 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(4 months ago)

US8299298 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
Feb, 2024

(4 months ago)

US8093423 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
Apr, 2026

(1 year, 9 months from now)

US10300039 KERYX BIOPHARMS Ferric citrate dosage forms
Jul, 2030

(6 years from now)

US9387191 KERYX BIOPHARMS Ferric citrate dosage forms
Jul, 2030

(6 years from now)



Auryxia is a drug owned by Keryx Biopharmaceuticals Inc. It is used for lowering and managing serum phosphorus levels. Auryxia uses Ferric Citrate as an active ingredient. Auryxia was launched by Keryx Biopharms in 2014. It is is available in tablet form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 21, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-790) Nov 06, 2020

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using FERRIC CITRATE ingredient

Market Authorisation Date: 05 September, 2014

Treatment: Control of serum phosphorous levels; Control of serum phosphorus levels

Dosage: TABLET

More Information on Dosage

AURYXIA family patents

Family Patents